A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

The use of immune checkpoint inhibitors is not associated with excess toxicity in people living with HIV and a concomitant diagnosis of cancer, indicate real-world results.

Authors: Alessia Villani, Luca Potestio, Gabriella Fabbrocini & Massimiliano Scalvenzi  Abstract Non-melanoma skin cancers, also known as keratinocyte tumors, have an increasing incidence worldwide, with basal cell carcinoma and squamous cell carcinoma being the most represented ones.

Authors: Henner Stege, Maximilian Haist, Ulrike Nikfarjam, Michael Schultheis, Jaqueline Heinz, Saskia Pemler, Carmen Loquai & Stephan Grabbe Abstract The global incidence of malignant melanoma, the leading cause of skin cancer death, has steadily increased in recent years.

Spencer and team also found differences by cancer type, with the largest treatment course reductions from 2019 to 2020 occurring among people with prostate cancer (77.0% in April) and non-melanoma skin cancer (72.4% in April).

Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.

The authors of the second study aimed to gain insight into the mechanism underlying the development of checkpoint inhibitor-mediated skin AEs by analyzing matched biopsies of tumor and skin tissue from 73 individuals with non-small-cell lung cancer who received nivolumab or pembrolizumab at one of four Swiss centers.

A systematic review of consensus recommendations for the management of rheumatoid arthritis in patients with cancer shows agreement in some areas, but highlights the need for further research into topics for which discrepancies exist.

Treatments can be divided into skin-directed therapies (SDTs) and systemic therapies. 

Individuals receiving treatment for psoriatic arthritis may have an increased risk for developing cancer, a meta-analysis indicates.

The analysis included data from 11,351 participants (67% men) with advanced or metastatic cancer (most commonly non-small-cell lung cancer and melanoma) enrolled in 20 trials comparing checkpoint inhibitors – specifically, nivolumab, pembrolizumab, ipilimumab and tremelimumab – with a control, such as chemotherapy or other immunologic compounds.